Pipeline

Carna has leveraged its expertise in kinase biology to establish an innovative product pipeline focused on cancer and immune disorders. We achieve success by coupling our deep understanding of cell signaling with our extensive drug discovery expertise to generate therapeutics that inhibit kinases and provide new treatment options for patients with high unmet medical needs.

Compound   Development Phase
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
Partner/
Collaboration Partner
SRA141 Indication:Cancer
Target:CDC7/ASK
SIERRA ONCOLOGY
AS-871 Indication:Autoimmune Diseases
Target:BTK
CB-1763
Indication:Blood Cancer, Immuno-Oncology
Target:BTK
Small
Molecule
Indication:Cancer, Immuno-Oncology
Target:Wnt-signal
National Cancer Center Japan
Small
Molecule
Indication:Psychiatry & neurology
Target:Kinase
Sumitomo Dainippon Pharma
Small
Molecule
Indication:Blood Cancer, Immuno-Oncology
Target:TGFβ signaling
HIROSHIMA UNIVERSITY
Small
Molecule
Indication:Autoimmune Diseases
Target:Kinase
Small
Molecule
Indication:Malaria
Target:N/A
KITASATO UNIVERSITY
Small
Molecule
Indication:Immuno-Oncology
Target:DGK
Small
Molecule
Indication:Cancer
Target:undisclosed
National Cancer Center Japan
Page Top